Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study

Gudmundsdottir, Hallbera; Möller, Páll Helgi; Jonasson, Jón G.; Bjõrnsson, Einar

doi:10.1080/00365521.2018.1553061

Cited by 20 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decreased survival has been associated with older age, the presence of symptoms, primary tumor location, tumor grade, and disease stage. 6,8,10 This study confirms the prognostic value of age for both OS and DSS, with a 4-to 5-fold increased risk of death in patients older than 60 years (i.e., median age). While survival also varied according to primary tumor location, only the appendix (with an excellent prognosis) and colon (with a more dismal prognosis) sites were significantly associated with prognosis.…”

Section: Discussionsupporting

confidence: 77%

“…1,3 Many factors including age, symptomatic disease, primary tumor location, disease stage, tumor grade, and primary surgical treatment are relevant for prognostic prediction. 6,8,10,28,29 In this study, the most common tumor origins were the small intestine (31.6%), appendix (25.3%), and pancreas (17.4%). This is in agreement with a Canadian population-based study, which indicated the small bowel as the predominant location, although pancreas NENs were not included in that report.…”

Section: Discussionmentioning

confidence: 59%

See 1 more Smart Citation

The overriding role of surgery and tumor grade for long‐term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population‐based cohort study

et al. 2021

View full text Add to dashboard Cite

Background: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) comprise a heterogeneous disease group. Factors that affect long-term survival remain uncertain.Complete population-representative cohorts with long-term follow-up are scarce.Aim: To evaluate factors of importance for the long-term survival.Methods and results: An Observational population-based study on consecutive GEP-NEN patients diagnosed from 2003 to 2013, managed according to national guidelines.Univariable and multivariable survival analyses were performed to evaluate overall survival (OS) and to identify independent prognostic factors. One hundred ninety eligible patients (males, 58.9%) (median age, 60.0 years; range, 10.0-94.2 years) were included.The small bowel, appendix, and pancreas were the most common tumor locations. The World Health Organization (WHO) tumor grade 1-3 distributions varied according to the primary location and disease stage. Primary surgery with curative intent was performed in 66% of the patients. The median OS of the study population was 183 months with 5-and 10-year OS rates of 66% and 57%, respectively. Only age, WHO tumor grade, and primary surgical treatment were independent prognostic factors for OS. Conclusion:The outcomes of GEP-NEN patients are related to several factors including age and primary surgical treatment. WHO tumor grading, based on the established criteria, should be routine in clinical practice. This may improve clinical decision-making and allow the comparison of outcomes among different centers.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 59%

The overriding role of surgery and tumor grade for long‐term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population‐based cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…One possible reason was that CHD occurs most frequently in small intestine NEN patients, accounting for 72% [ 32 ]. Another plausible explanation was that pancreatic NEN patients had an advanced tumor stage, so they might not have a long enough life expectancy to die of CVD [ 28 , 37 , 38 ], which may explain the lower risk of CVM in patients with grade III/IV (HR: 0.701; 95% CI: 0.533-0.923) or distant tumor stage (HR: 0.456; 95% CI: 0.382-0.544).…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry‐Based Analysis

Sun

Wang

2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. This research is aimed to explore mortality patterns and quantitatively assess the risks of cardiovascular mortality (CVM) in patients with primary gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Methods. We extracted data from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with GEP-NENs between 2000 and 2015. The standardized mortality ratio (SMR) and the absolute excess risk were obtained based on the reference of the general US population. The cumulative incidence function curves were constructed for all causes of death. Predictors for CVM were identified using a multivariate competing risk model. Results. Overall, 42027 patients were enrolled from the SEER database, of whom 1598 (3.8%) died from cardiovascular disease (CVD). The SMR for CVM was 1.20 (95% CI: 1.14-1.26) among GEP-NEN patients. The cumulative mortality of CVD was the lowest among all causes of death, including primary cancer, other cancer, and other noncancer diseases. Furthermore, age at diagnosis, race, Hispanic origin, sex, marital status, year of diagnosis, grade, education level, region, SEER stage, primary site, surgery, and chemotherapy were identified as independent predictors of CVM in GEP-NEN patients. Conclusions. GEP-NEN patients have a significantly increased risk of CVM relative to the general population. Cardioprotective interventions might be considered a preferred method for these patients.

show abstract

“…The incidence has also risen compared to the prior study conducted in the Netherlands, which dates from 2001 [5]. Previous population-based studies conducted in Europe reported comparable increased incidence rates: 0.29 in Austria (2004-2005, grade 1 and 2 only), 0.30 in Italy (1981-2005, grades not reported), 0.80 in Iceland (2000-2014, grades not reported) and 0.81 in Norway (1993-2004, grades not reported), per 100.000 persons (18)(19)(20)(21). Another explanation for the increase in incidence is an ageing population.…”

Section: Discussionmentioning

confidence: 76%

Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands

et al. 2021

View full text Add to dashboard Cite

Background Small bowel neuroendocrine neoplasms (SB-NEN) are rare cancers, population-based studies are needed to study this rare indolent disease. The aim of this study was to explore trends in epidemiology, treatment and survival outcomes of patients with SB-NEN based on Dutch nationwide data. Patients and methods Patients with grade 1 or 2 SB-NEN diagnosed between 2005 and 2015 were retrieved from the Netherlands Cancer Registry and linked to The Nationwide Network and Registry of Histo- and Cytopathology in the Netherlands. Age-adjusted incidence rates were calculated based using the direct standardization method. Survival analyses were performed with the Kaplan–Meier method. Results A total of 1132 patients were included for epidemiological analyses. The age-adjusted incidence rate of SB-NEN increased from 0.52 to 0.81 per 100.000 person-years between 2005 and 2015. Incidence was higher for males than females (0.93 vs. 0.69 in 2015). Most patients had grade 1 tumours (83%). Surgery was performed in 86% of patients, with resection of the primary tumour in 99%. During the study period, administration of somatostatin analogues (SSAs) increased from 5 to 22% for stage III and from 27 to 63% for stage IV disease. Mean follow-up was 61 (standard deviation 38) months. Survival data were complete for 975/1132 patients and five-year overall survival was 75% for stage I-II, 75% for stage III and 57% for stage IV. Conclusions This study shows an increase in the incidence of SB-NEN in the Netherlands. A predominant role of surgery was found in all disease stages. Use of SSAs has increased over time.

show abstract

Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study

Cited by 20 publications

References 22 publications

The overriding role of surgery and tumor grade for long‐term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population‐based cohort study

The overriding role of surgery and tumor grade for long‐term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population‐based cohort study

Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry‐Based Analysis

Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands

Contact Info

Product

Resources

About